Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec:204:104533.
doi: 10.1016/j.critrevonc.2024.104533. Epub 2024 Oct 22.

Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options

Affiliations
Review

Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options

Miriam Forte et al. Crit Rev Oncol Hematol. 2024 Dec.

Abstract

Endometrial cancer incidence and related mortality are on the rise due to aging demographics. This population often presents with unfavorable features, such as myometrial invasion, non-endometrioid histology, high-grade tumors, worse prognosis, etc. The role of age as an independent prognostic factor is still debated, and screening tools addressing frailty emerge as pivotal in guiding treatment decisions; however, they are still underutilized. Treatment disparities are evident in the case of older patients with endometrial cancer, who frequently receive suboptimal care, hindering their survival. Radiotherapy and minimally invasive surgical approaches could be performed in older patients. Data on chemotherapy and immunotherapy are scarce, but their potential remains promising and data are being gathered by recent trials, contingent on optimal patient selection through geriatric assessments. Overall, we recommend personalized, screening tool-guided approaches, adherence to guideline-recommended treatments, and inclusion of older people in clinical trials to help identify the best course of treatment.

Keywords: Age; Elderly; Endometrial cancer; Frailty; Geriatric assessment.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Teresa Troiana received honoraria and research funding from Amgen, Novartis Bristol, Pierre Fabre, MSD, and Bayer. Sandro Pignata received honoraria from MSD, AstraZeneca, GSK, PharmaMar, Roche, Norvartis, and research funding from Roche, Pfizer, MSD, GSK, and AstraZeneca. The other Authors declare no conflict of interest related to this work.

LinkOut - more resources